Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV real-world evaluation of LacTEST for diagnosing hypolactasia in children with lactose intolerance symptoms
2025-521294-13-00Phase 4Authorised
- Sponsor
- Venter Pharma
- Start
- Jun 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Gaxilose in lactase deficiency, sponsored by Venter Pharma. Primary endpoint: Primary diagnostic performance at 5 hours using 19.18 mg xylose cut-off. Planned start Jun 2025; status: authorised.
02
Drugs
Gaxilose
03
Conditions
lactase deficiency
Beyond the preview
Go deeper on 2025-521294-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521294-13-00.